Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.

× No keyword cloud information.

7 in total

1. In-vitro cidal activity of clarithromycin and its 14-hydroxy metabolite (A-62671) against Haemophilus influenzae.

Authors: M Powell; H Y Chen; B Weinhardt; J D Williams
Journal: J Antimicrob Chemother Date: 1991-05 Impact factor: 5.790

2. Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin.

Authors: P B Fernandes; N Ramer; R A Rode; L Freiberg
Journal: Eur J Clin Microbiol Infect Dis Date: 1988-02 Impact factor: 3.267

3. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors: D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal: Antimicrob Agents Chemother Date: 1990-07 Impact factor: 5.191

4. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests.

Authors: H Dabernat; C Delmas; M Seguy; J B Fourtillan; J Girault; M B Lareng
Journal: J Antimicrob Chemother Date: 1991-02 Impact factor: 5.790

5. The development of macrolides: clarithromycin in perspective.

Authors: H C Neu
Journal: J Antimicrob Chemother Date: 1991-02 Impact factor: 5.790

6. The in-vitro and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite.

Authors: M N Logan; J P Ashby; J M Andrews; R Wise
Journal: J Antimicrob Chemother Date: 1991-02 Impact factor: 5.790

7. Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test.

Authors: A L Barry; P B Fernandes; J H Jorgensen; C Thornsberry; D J Hardy; R N Jones
Journal: J Clin Microbiol Date: 1988-11 Impact factor: 5.948

7 in total

2 in total

Review 1. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.

Authors: H D Langtry; R N Brogden
Journal: Drugs Date: 1997-06 Impact factor: 9.546

2. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans.

Authors: R Pajukanta; S Asikainen; M Saarela; S Alaluusua; H Jousimies-Somer
Journal: Antimicrob Agents Chemother Date: 1992-06 Impact factor: 5.191

2 in total